Autosomal Dominant Polycystic Kidney Disease
Conditions
Brief summary
This study will analyze the germline and somatic mutations underlying the development of ADPKD in order to better understand the genetic mechanism responsible for the cystic transformation. Once identified, these mutations could help us understand better the mechanism leading to the development of this disease and may explain at least in part the phenotypic variability.
Detailed description
The presentation of ADPKD renal and extrarenal manifestations varies widely, even within families, and has been attributed to numerous genetic factors. One principal explanation came with the discovery that renal cyst lining cells from ADPKD patients undergo secondary somatic mutations, selective loss of the second copy of a respective normal polycystic kidney disease (PKD) gene. These somatic mutations can occur in either polycystic kidney disease 1 (PKD1) or polycystic kidney disease 2 (PKD2). Furthermore, various cysts in the same patient have been reported to harbor different somatic mutations. These findings implicated a cellular recessive mechanism for cyst formation in ADPKD, suggesting the possibility that the observed intra-familial variation in disease phenotype may, at least in part, be explained by variation in mutation type, the timing and number of somatic "second-hit" mutations in individual family members affected with the disease. However, there is currently very little known about the cellular genetic mechanism leading to cysts development and very few studies, addressing this issue.
Interventions
None listed
Sponsors
Study design
Eligibility
Inclusion criteria
* Males or females * 18 years of age or older * Confirmed diagnosis of ADPKD * Undergoing a native nephrectomy * Willing and able to provide informed consent
Exclusion criteria
* Unable or unwilling to provide informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The presence of somatic PKD 1/2 gene mutations in cyst epithelial cells | 10 YEARS | The presence of mutations will be measured by next generation sequencing (NGS) and other tools for mutation analysis. |
Countries
United States
Contacts
Weill Medical College of Cornell University